Janux Therapeutics (JANX) Shares Outstanding (Weighted Average) (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $62.7 million in Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $62.7 million, up 1.41% year-over-year; the trailing twelve-month figure through Mar 2026 was $62.7 million (up 1.41% YoY), and the FY2025 annual result was $62.0 million, up 15.28% from the prior year.
• Shares Outstanding (Weighted Average) climbed to $62.7 million in Q1 2026 per JANX's latest filing, from $62.0 million in the prior quarter.
• Over five years, Shares Outstanding (Weighted Average) peaked at $62.7 million in Q1 2026 and troughed at $41.3 million in Q1 2022.
• A 5-year average of $50.3 million and a median of $49.0 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
• The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Weighted Average) soared 8975.72% in 2022, then advanced 0.85% in 2023.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $41.5 million in 2022, then gained by 6.14% to $44.0 million in 2023, then grew by 22.12% to $53.8 million in 2024, then advanced by 15.28% to $62.0 million in 2025, then increased by 1.13% to $62.7 million in 2026.
• Business Quant data shows JANX's Shares Outstanding (Weighted Average) at $62.7 million in Q1 2026, $62.0 million in Q4 2025, and $61.9 million in Q3 2025.